Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
ACIU
#6082
AC Immune SA
2.9
3
-0.34%
Sektor:
Basis:
Gewinnwährung:
Tagesspanne
Jahresspanne
Tagesänderung
-0.34%
Monatliche Änderung
-17.93%
6 month change
+42.23%
Jahresänderung
+14.45%
Vorheriger Schlusskurs
2.9
4
Open
2.9
3
Bid
Ask
Low
2.9
3
High
2.9
3
Volumen
17
Märkte
Aktien
Gesundheitswesen
ACIU
Open full chart
Financials
Overview
Finanzbericht
Statistics
Dividends
Quarterly
Annual
Income statement
Balance sheet
Cash flow
Value
2020
2021
2022
2023
2024
Total assets
—
—
—
—
—
Total liabilities
—
—
—
—
—
Total equity
—
—
—
—
—
Total liabilities & shareholders' equities
—
—
—
—
—
Total debt
—
—
—
—
—
Net debt
—
—
—
—
—
Nachrichten
AC Immune startet Phase-1-Studie für hirngängigen NLRP3-Inhibitor
AC Immune begins phase 1 trial of brain-penetrant NLRP3 inhibitor
2026 Market Outlook: Focus On Pharma For Consistent Returns, Potential Skyrocketing Shares
AC Immune: Maintaining 'Buy' Rating On Next Steps For ACI-7104.056 Development In PD
Tesla and Rivian among market cap stock movers on Friday
AC Immune Trial Shows Early Signs Immunotherapy May Slow Parkinson's - AC Immune (NASDAQ:ACIU)
Positive Studiendaten zu Parkinson-Mittel beflügeln AC Immune-Aktie
AC Immune stock rises after positive Parkinson’s disease trial data
AC Immune’s Parkinson’s treatment shows promise in slowing disease
AC Immune (ACIU) Reports Q3 Loss, Lags Revenue Estimates
Alector (ALEC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline